WCG Announces — Clinical Trials in the Precision Medicine Era: New Techniques, New Complexity, Free Virtual Roundtable, Aug. 23, 2018

Share Article

The new world of genetic testing in clinical trials is here. Join WCG and InformedDNA to understand and overcome the challenges of the new era.

Clinical Trials in the Precision Medicine Era:
New Techniques, New Complexity
**WCG Free Virtual Roundtable**
Aug. 23, 2018 — 1:30 p.m. – 3:00 p.m. ET
http://info.fdanews.com/clinical-trials-in-the-precision-medicine-era

Drug pipelines are changing and sponsors are focusing on highly targeted therapies. To do that effectively, investigators must rely on genetic testing.

But that’s easier said than done.

Historically a Phase III trial would collect about a million data points; with genetic testing that’s increased to 3 to 5 million data points. And to enroll the right patients, genetic testing often must be done before someone enters a trial.

That volume of highly complex data leaves many investigators struggling to explain results to patients. It can be daunting.

That’s where a new partnership between WCG and InformedDNA can help.

Mark the calendar for Aug. 23 when CenterWatch brings you a FREE virtual roundtable, featuring WCG’s Chief Medical Officer Lindsay McNair, InformedDNA’s Karmen Trzupek and Jill Johnston of WCG’s Site Management Group.

These three highly engaging genetic and trial experts will bring you the their best advice for thriving in this brave new clinical trial world.

Meet the Presenters:
Lindsay McNair MD MPH MSBioethics, moderator: Dr. McNair is Chief Medical Officer of the WIRB-Copernicus Group (WCG). She has consulted to numerous biopharma companies, providing medical guidance on clinical development strategies and study designs for new drug studies and medical oversight of all phases of clinical trials. She now oversees the physician team within the WCG IRBs, providing support to pharma/biotech companies on protocol design, regulatory compliance, human subject protection, and ethical policy development.

Karmen Trzupek MS CGC is Director, Ocular and Rare Disease Genetics Services for InformedDNA. A Certified Genetics Counselor, she has extensive experience with macular degeneration, Usher syndrome and other retinal diseases with a heritability component.

Jill Johnston is President, Site Activation, WCG Clinical Services, charged with developing strategy, driving the vision, and delivering for customers in clinical trial site identification, selection, and activation. With 25+ years in clinical research, Ms. Johnston is an expert in clinical business strategy, transformation, innovation, pharmaceutical efficiency, and clinical research operations.

Who Will Benefit:

  •     Clinical trial sponsors/operators/CROs
  •     Medical directors
  •     Researchers
  •     Trial designers
  •     Patient recruiters
  •     Regulatory/compliance

Virtual Roundtable Details:
Clinical Trials in the Precision Medicine Era:
New Techniques, New Complexity
**WCG Free Virtual Roundtable**
Aug. 23, 2018 — 1:30 p.m. – 3:00 p.m. ET
http://info.fdanews.com/clinical-trials-in-the-precision-medicine-era

Easy Ways to Register:
Online:     http://info.fdanews.com/clinical-trials-in-the-precision-medicine-era
By phone: 888-838-5578 or 703-538-7600

WIRB-Copernicus Group® (WCG):
The pioneer of independent ethical review, WCG continues to drive ingenuity in the clinical research space. Today, WCG’s solutions are built upon the foundation of ethical review, but have grown to include a suite of complementary services and technologies that expand the capabilities of the modern research professional. WCG delivers transformational solutions that stimulate growth, foster compliance, and maximize efficiency for those who perform clinical trials.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDAnews
+1 703-538-7600
Email >
Visit website